Cargando…
Co-targeting KRAS G12C and EGFR reduces both mutant and wild-type RAS-GTP
The combination of KRAS G12C inhibitors with EGFR inhibitors has reproducibly been shown to be beneficial. Here, we identify another benefit of this combination: it effectively inhibits both wild-type and mutant RAS. We believe that targeting both mutant and wild-type RAS helps explain why this comb...
| Autores principales: | , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group UK
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9684405/ https://www.ncbi.nlm.nih.gov/pubmed/36418474 http://dx.doi.org/10.1038/s41698-022-00329-w |